Cement bentonite cutoff walls for polluted sites

Cement-bentonite (CB) cutoff walls have long been used to control ground water flow and contaminant migration at polluted sites. Hydraulic conductivity and unconfined compressive strength are two short-term properties often used by industry and owners in CB specification and are important parameters discussed in this paper. For polluted sites, long-term compatibility is also an important issue. These properties are coupled to a number of external factors including the mix design, construction sequence, presence/absence of contaminants at the site. Additional short-term properties for engineering assessment include the stressstrain characteristics in both drained and undrained shear in both with and without confinement as well as one-dimensional consolidation properties. Long term CB properties are affected by aging, reaction chemistry, drying, in situ stress state, and interaction with the polluted environment. © 2013 Taylor & Francis Group.

Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.

AIMS: Regenerative medicine is an emerging field with the potential to provide widespread improvement in healthcare and patient wellbeing via the delivery of therapies that can restore, regenerate or repair damaged tissue. As an industry, it could significantly contribute to economic growth if products are successfully commercialized. However, to date, relatively few products have reached the market owing to a variety of barriers, including a lack of funding and regulatory hurdles. The present study analyzes industry perceptions of the barriers to commercialization that currently impede the success of the regenerative medicine industry in the UK. MATERIALS & METHODS: The analysis is based on 20 interviews with leading industrialists in the field. RESULTS: The study revealed that scientific research in regenerative medicine is thriving in the UK. Unfortunately, lack of access to capital, regulatory hurdles, lack of clinical evidence leading to problems with reimbursement, as well as the culture of the NHS do not provide a good environment for the commercialization of regenerative medicine products. CONCLUSION: Policy interventions, including increased translational government funding, a change in NHS and NICE organization and policies, and regulatory clarity, would likely improve the general outcomes for the regenerative medicine industry in the UK.

Innovation processes within the healthcare industry: Determining critical success factors aligned to product strategies

The impact of differing product strategies on product innovation processes pursued by healthcare firms is discussed. The critical success factors aligned to product strategies are presented. A definite split between pioneering product strategies and late entrant product strategies is also recognised.